New findings on inhibitor development: from registries to clinical studies

F. Peyvandi, C. E. Ettingshausen, J. Goudemand, V. Jiménez-Yuste, E. Santagostino, M. Makris

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

The high incidence of inhibitors against factor VIII (FVIII) concentrates in patients with haemophilia A has encouraged debate as to whether product-type plays a role. There is debate in the literature as to whether rFVIII concentrates are associated with a higher incidence of inhibitors compared to pdFVIII products. The management of haemophilia in patients with inhibitors includes on-demand/prophylaxis treatment with bypassing agents, and/or immune tolerance induction (ITI). However, these options create an economic and emotional burden on patients, their families and healthcare practitioners. Although ITI eliminates inhibitors successfully in 60–80% of cases, it is costly. Despite high costs, preliminary data from a decision analytical model have indicated that ITI is economically advantageous compared with on-demand/prophylactic treatment with bypassing agents. In patients with persistent inhibitors and those who are not candidates for ITI or have failed ITI, bleeding-related mortality and morbidity increase and quality of life decreases, compared with non-inhibitor patients. This article provides an update on the risk of inhibitor development and discusses best management approaches for patients with high-risk factors for inhibitor development.

Original languageEnglish
Pages (from-to)4-13
Number of pages10
JournalHaemophilia
Volume23
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Immune Tolerance
Registries
Hemophilia A
Incidence
Factor VIII
Clinical Studies
Economics
Quality of Life
Hemorrhage
Morbidity
Delivery of Health Care
Costs and Cost Analysis
Mortality
Therapeutics

Keywords

  • factor concentrate
  • factor VIII
  • haemophilia A
  • inhibitor burden
  • inhibitor development
  • previously untreated patients

ASJC Scopus subject areas

  • Hematology
  • Genetics(clinical)

Cite this

New findings on inhibitor development : from registries to clinical studies. / Peyvandi, F.; Ettingshausen, C. E.; Goudemand, J.; Jiménez-Yuste, V.; Santagostino, E.; Makris, M.

In: Haemophilia, Vol. 23, 01.01.2017, p. 4-13.

Research output: Contribution to journalReview article

Peyvandi, F. ; Ettingshausen, C. E. ; Goudemand, J. ; Jiménez-Yuste, V. ; Santagostino, E. ; Makris, M. / New findings on inhibitor development : from registries to clinical studies. In: Haemophilia. 2017 ; Vol. 23. pp. 4-13.
@article{0d2ce4ae80a149b2a1d05dfd7e2b7f00,
title = "New findings on inhibitor development: from registries to clinical studies",
abstract = "The high incidence of inhibitors against factor VIII (FVIII) concentrates in patients with haemophilia A has encouraged debate as to whether product-type plays a role. There is debate in the literature as to whether rFVIII concentrates are associated with a higher incidence of inhibitors compared to pdFVIII products. The management of haemophilia in patients with inhibitors includes on-demand/prophylaxis treatment with bypassing agents, and/or immune tolerance induction (ITI). However, these options create an economic and emotional burden on patients, their families and healthcare practitioners. Although ITI eliminates inhibitors successfully in 60–80{\%} of cases, it is costly. Despite high costs, preliminary data from a decision analytical model have indicated that ITI is economically advantageous compared with on-demand/prophylactic treatment with bypassing agents. In patients with persistent inhibitors and those who are not candidates for ITI or have failed ITI, bleeding-related mortality and morbidity increase and quality of life decreases, compared with non-inhibitor patients. This article provides an update on the risk of inhibitor development and discusses best management approaches for patients with high-risk factors for inhibitor development.",
keywords = "factor concentrate, factor VIII, haemophilia A, inhibitor burden, inhibitor development, previously untreated patients",
author = "F. Peyvandi and Ettingshausen, {C. E.} and J. Goudemand and V. Jim{\'e}nez-Yuste and E. Santagostino and M. Makris",
year = "2017",
month = "1",
day = "1",
doi = "10.1111/hae.13137",
language = "English",
volume = "23",
pages = "4--13",
journal = "Haemophilia",
issn = "1351-8216",
publisher = "Wiley-Blackwell Publishing Ltd",

}

TY - JOUR

T1 - New findings on inhibitor development

T2 - from registries to clinical studies

AU - Peyvandi, F.

AU - Ettingshausen, C. E.

AU - Goudemand, J.

AU - Jiménez-Yuste, V.

AU - Santagostino, E.

AU - Makris, M.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - The high incidence of inhibitors against factor VIII (FVIII) concentrates in patients with haemophilia A has encouraged debate as to whether product-type plays a role. There is debate in the literature as to whether rFVIII concentrates are associated with a higher incidence of inhibitors compared to pdFVIII products. The management of haemophilia in patients with inhibitors includes on-demand/prophylaxis treatment with bypassing agents, and/or immune tolerance induction (ITI). However, these options create an economic and emotional burden on patients, their families and healthcare practitioners. Although ITI eliminates inhibitors successfully in 60–80% of cases, it is costly. Despite high costs, preliminary data from a decision analytical model have indicated that ITI is economically advantageous compared with on-demand/prophylactic treatment with bypassing agents. In patients with persistent inhibitors and those who are not candidates for ITI or have failed ITI, bleeding-related mortality and morbidity increase and quality of life decreases, compared with non-inhibitor patients. This article provides an update on the risk of inhibitor development and discusses best management approaches for patients with high-risk factors for inhibitor development.

AB - The high incidence of inhibitors against factor VIII (FVIII) concentrates in patients with haemophilia A has encouraged debate as to whether product-type plays a role. There is debate in the literature as to whether rFVIII concentrates are associated with a higher incidence of inhibitors compared to pdFVIII products. The management of haemophilia in patients with inhibitors includes on-demand/prophylaxis treatment with bypassing agents, and/or immune tolerance induction (ITI). However, these options create an economic and emotional burden on patients, their families and healthcare practitioners. Although ITI eliminates inhibitors successfully in 60–80% of cases, it is costly. Despite high costs, preliminary data from a decision analytical model have indicated that ITI is economically advantageous compared with on-demand/prophylactic treatment with bypassing agents. In patients with persistent inhibitors and those who are not candidates for ITI or have failed ITI, bleeding-related mortality and morbidity increase and quality of life decreases, compared with non-inhibitor patients. This article provides an update on the risk of inhibitor development and discusses best management approaches for patients with high-risk factors for inhibitor development.

KW - factor concentrate

KW - factor VIII

KW - haemophilia A

KW - inhibitor burden

KW - inhibitor development

KW - previously untreated patients

UR - http://www.scopus.com/inward/record.url?scp=85006446531&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006446531&partnerID=8YFLogxK

U2 - 10.1111/hae.13137

DO - 10.1111/hae.13137

M3 - Review article

AN - SCOPUS:85006446531

VL - 23

SP - 4

EP - 13

JO - Haemophilia

JF - Haemophilia

SN - 1351-8216

ER -